Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 13, 2025 Cellectar Biosciences, Inc. beats earnings expectations. Reported EPS is ...
Nonalcoholic Steatohepatitis Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...
Ophthalmology Times4d
FDA accepts new drug application for low-dose atropine from Sydnexis
The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.
Rheumatology Advisor2d
FDA Drug Approval Decisions Expected in April 2025
Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.
News-Medical.Net3d
Key benefits of outsourcing regulatory submission content development
Discover how outsourcing regulatory submission content development improves efficiency and ensures compliance.
Healio3d
FDA accepts new drug application for SYD-101 to treat pediatric myopia progression
The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription ...
The Manila Times1d
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
Company expects to submit New Drug Application (NDA) in April 2025 - DEER PARK, Ill., March 14, 2025 (GLOBE NEWSWIRE) -- Eton ...
These have the potential to generate employment to 3.12 lakh people, he says
Andhra Pradesh SIPB approves ₹3.10 lakh crore investments, targeting 3.12 lakh jobs, including major projects by ...
The Manila Times4d
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development ...
Nature4d
Upcoming FDA approval decisions in Q2 2025
If approved, clesrovimab will directly compete ... The FDA has accepted a New Drug Application (NDA) for sebetralstat for the on-demand treatment of HAE attacks in adult and paediatric patients ...
Zacks Investment Research on MSN1d
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?
Axsome Therapeutics’ AXSM Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio ...